|
|
 Previous Article | Table of Contents | Next Article 
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic
veno-occlusive disease in patients with hyperbilirubinemia after bone
marrow transplantation
C Salat, E Holler, HJ Kolb, B Reinhardt, R Pihusch, W Wilmanns and E Hiller
Medical Klinik III Klinikum Grosshadern der Ludwig-Maximilians- Universitat
Munchen, Germany.
Hepatic veno-occlusive disease (VOD) is a frequent and severe complication
after bone marrow transplantation (BMT). We previously have described
plasminogen activator inhibitor-1 (PAI-1) as a possible marker of VOD. To
confirm the significance of this finding, we now determined PAI-1 levels in
31 of 186 consecutive patients undergoing BMT who developed
hyperbilirubinemia greater than 3 mg/dL for various reasons. Diagnoses were
made by clinical criteria and confirmed by biopsy in 23 of 31 patients.
They included VOD (n = 7), acute graft- versus-host disease (GVHD) of the
liver (n = 7), and other hepatic injury (n = 17). PAI-1 (mean +/- SD) was
significantly (P < .001) elevated in patients with VOD (321.6 +/- 161.2
ng/mL) as compared with patients with GVHD (22.8 +/- 8.4 ng/mL) or other
hepatic damage (32.8 +/- 30.8 ng/mL) at the timepoint of bilirubin
increase. At the peak bilirubin concentration, the corresponding PAI-1
levels were 426.1 +/- 230.0 ng/mL in patients with VOD, 41.0 +/- 20.6 ng/
mL in patients with GVHD, and 44.6 +/- 32.9 ng/mL in patients with other
hepatic injury (P < .001 VOD v GVHD/other hepatic injury). Our results
underline the relevance of PAI-1 in the differential diagnosis of
hyperbilirubinemia after BMT and its significance as a sensitive and
specific marker of severe VOD.
Volume 89,
Issue 6,
pp. 2184-2188,
03/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Benimetskaya, S. Wu, A. M. Voskresenskiy, C. Echart, J.-F. Zhou, J. Shin, M. Iacobelli, P. Richardson, K. Ayyanar, and C. A. Stein
Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease
Blood,
November 15, 2008;
112(10):
4343 - 4352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Yanik, V. T. Ho, J. E. Levine, E. S. White, T. Braun, J. H. Antin, J. Whitfield, J. Custer, D. Jones, J. L. M. Ferrara, et al.
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
Blood,
October 15, 2008;
112(8):
3073 - 3081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, L. D. DeLeve, P. S. Kamath, and A. Tefferi
Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation
Mayo Clin. Proc.,
May 1, 2003;
78(5):
589 - 598.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, C. Murakami, Z. Jin, D. Warren, P. Momtaz, D. Hoppensteadt, A. D. Elias, J. H. Antin, R. Soiffer, T. Spitzer, et al.
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
Blood,
December 15, 2002;
100(13):
4337 - 4343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Pogliani, P. Perseghin, M. Parma, P. Pioltelli, and G. Corneo
Defibrotide in Recurrent Thrombotic Thrombocytopenic Purpura
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2000;
6(2):
69 - 70.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Petäjä, S. Pitkänen, K. Vettenranta, A. Fasth, and M. Heikinheimo
Serum Tumor Marker CA 125 Is an Early and Sensitive Indicator of Veno-Occlusive Disease in Children Undergoing Bone Marrow Transplantation
Clin. Cancer Res.,
February 1, 2000;
6(2):
531 - 535.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. G. Richardson, A. D. Elias, A. Krishnan, C. Wheeler, R. Nath, D. Hoppensteadt, N. M. Kinchla, D. Neuberg, E. K. Waller, J. H. Antin, et al.
Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population
Blood,
August 1, 1998;
92(3):
737 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
